Thrombolytics and Myocardial Infarction

  1. Lookup NU author(s)
  2. Dr Vijay Kunadian
Author(s)Kunadian V, Gibson CM
Publication type Article
JournalCardiovascular Therapeutics
Year2012
Volume30
Issue2
Pagese81-e88
ISSN (print)1755-5914
ISSN (electronic)1755-5922
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Coronary artery disease is the single leading cause of death in the United States. Occlusion of the coronary artery was identified to be the cause of myocardial infarction almost a century ago. Following a series of investigations, streptokinase was discovered and demonstrated to be beneficial for the treatment of patients with acute myocardial infarction in terms of reducing short- and long-term mortality. Newer agents including tissue plasminogen activators such as alteplase, reteplase, tenecteplase were developed subsequently. In the present era, thrombolytic therapy and primary percutaneous coronary intervention has revolutionized the way patients with acute myocardial infarction are managed resulting in significant reduction in cardiovascular death. This article provides an overview of the various thrombolytic agents utilized in the management of patients with acute myocardial infarction.
PublisherWiley-Blackwell Publishing Ltd.
URLhttp://dx.doi.org/10.1111/j.1755-5922.2010.00239.x
DOI10.1111/j.1755-5922.2010.00239.x
Actions    Link to this publication